上海艾力斯医药科技股份有限公司任命牟艳萍为公司首席执行官

2020年3月26日（上海）上海艾力斯医药科技股份有限公司今日宣布，任命牟艳萍女士为上海艾力斯医药科技股份有限公司（以下简称“艾力斯”）首席执行官，全面负责公司业务运营，向公司创始人、董事长杜锦豪先生汇报。

       牟艳萍女士深耕中国医药市场二十多年，曾先后服务于包括葛兰素史克、阿斯利康、强生、默沙东在内的多家知名的跨国制药企业，并在领导销售、市场营销与综合管理方面积累了广泛经验。在加入艾力斯之前，牟艳萍女士在默沙东担任肿瘤事业部董事总经理，创建了默沙东中国肿瘤事业部。在牟艳萍女士的领导下，默沙东中国肿瘤事业部在创建后不到三年的时间内，跻身外资医药企业肿瘤业务的三甲。

       “上海艾力斯自创立以来，一直致力于创新药的研发，未来公司的战略目标更是要将艾力斯建成集研发、生产、销售为一体的创新型现代制医药企业。目前正是公司发展和转型的关键阶段；牟艳萍女士不但有国内实战经验，而且还具备国际视野，在此时加入艾力斯，必将加速推动公司发展，推进公司转型，对于艾力斯实现公司愿景是如虎添翼。”上海艾力斯医药科技股份有限公司创始人、董事长杜锦豪先生表示。

       “我非常认同杜锦豪董事长以及艾力斯的愿景和战略，也很敬佩公司在过去十余年中对创新药研发的执着追求，及不惜为此投入的巨大人力和财力；公司未来的目标是在不断强化自身研发创新药能力的同时，引进创新产品，并走向世界，这是吸引我加入艾力斯的最重要的一点。我对艾力斯的未来有信心，也很期待与艾力斯的团队共同成长。”牟艳萍女士表示。

       牟艳萍女士于1989年毕业于复旦大学上海医学院，获得医学学士学位， 并开始从事临床医生工作，直至1996年，牟艳萍女士选择转投制药企业工作。在2014年，她获得中欧国际工商学院EMBA学位。

Shanghai Allist Appoints Sandy Mou as CEO

March 26th, 2020（Shanghai）Shanghai Allist Pharmaceutical Technology Co., Ltd today announced that Dr. Sandy Mou has been appointed as the Chief Executive Officer of the company, effective immediately. Dr. Mou will oversee the overall company operation and report directly to the Founder of the company and the Chairman of the Board,Mr. Jinhao Du.

Dr. Mou is an over-20-year veteran of theChina pharmaceutical industry, having served previously in multi-national pharmaceutical giants including Glaxo-Smith-Kline (GSK）,AstraZeneca, Johnson & Johnson (J &J), and Merck Sharp & Dome (MSD)

Before joining Allist, Dr. Mou served as the General Manager of the Oncology Business Unit of MSD, during which time she set up the operation practically from scratch, led a team of one thousand that drove record-breaking growth, and eventually elevated MSD into the top three rank of the oncology business in China.

“With a historical commitment to the research and development of innovative medicines, Allist has recently embarkedon a new journey to transform itself into a new generation of full-fledged and innovation-driven modern pharmaceutical company, with developed capability in the discovery,production and commercialization of innovative medicines.  We are excited about Dr. Mou joining Allist,and are confident that her strong expertise, global vision and tremendous leadership will help the company enormously in realizing its corporate vision”, remarked Mr. Jighao Du, the Chairman of the Board of Allist.

“I am very much drawn to Allist’s corporate vision and its growth strategy, and I am also extremely impressed at the company’s relentless pursuit of innovative medicines as evidenced by the tremendous investment the company has made over the past 10 years to R&D”, said Dr. Mou. She added that she was also excited about the future of Allist with its strengthened efforts to beef up its internal R&D capability while also focusing on forging strategic international partnership to bring to China innovative medicines. “I have great confidence in the future of Allist and I am looking forward to working with a great team to grow the company together”,said Dr. Mou.

Dr.Mou graduated from the Shanghai Medical College of Fudan University with a Bachelorof Medicine degree in 1989. She was a practice clinician until 1996 when she decided to seek her career development in the pharmaceutical industry. Dr. Mou received her EMBA from CEIBS in 2014.